Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoantigen Vaccines in Combination with Immune Checkpoint Inhibitors for Maintenance Therapy Following Definitive Treatment of Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma: an Open-Label, Randomized, Phase II Study

NCT06675201 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06675201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06675201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoantigen Vaccines in Combination with Immune Checkpoint Inhibitors for Maintenance Therapy Following Definitive Treatment of Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma: an Open-Label, Randomized, Phase II Study
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
October 1, 2027
Enrollment
165 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma (escc), immune checkpoint inhibitors (icis), neoantigen-loaded dendritic cell vaccine